Tesamorelin
Also known as: Egrifta, GHRH analog HIV lipodystrophy
Clinical and translational research on tesamorelin, an FDA-approved GHRH analog for HIV-associated lipodystrophy, and related metabolic studies.
What does the research say about Tesamorelin?
Tesamorelin reduces visceral adipose tissue in HIV lipodystrophy trials and is studied for broader metabolic endpoints. Synapse links guideline-adjacent reviews, RCTs, and investigator networks.
Synapse surfaces peer-reviewed research and researcher networks for informational purposes only. This page does not provide medical advice, dosing guidance, or treatment recommendations.
Research feed: Tesamorelin
11 indexed papers matched to curated MeSH concepts in the last 90 days.
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
Clinical cases illustrate how distinct treatments affect excess visceral abdominal fat in individuals living with HIV, suggesting tailored approaches.
Comorbidities and treatment regimens of HIV-associated lipodystrophy disease among a cohort of persons with HIV in Washington, DC
Observational study reports associations between comorbidities and treatment regimens in persons with HIV with lipodystrophy.
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model
Dolutegravir or classical cART combined with high-calorie diets induced significant myocardial fibrosis (P<0.0001) and deleterious ECG changes in rats, an effect prevented by tesamorelin.
May warrant ECG monitoring in dolutegravir-treated PLWH; hypothesis-generating for diet-cART interactions in myocardial fibrosis.
Peptidomimetic Long-Acting Growth Hormone-Releasing Hormone Agonists Promote Tissue Perfusion in Hindlimb Ischemia
Hybrid GHRH analogs improve tissue perfusion in ischemic hindlimb, suggesting new therapeutic avenues for vascular diseases.
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications
Structured narrative review summarizes injectable peptides' evidence, safety, and antidoping implications in sports medicine.
Therapeutic potential of growth hormone-releasing hormone analogues in cardiovascular and cerebrovascular diseases: mechanisms and preclinical evidence
Narrative review highlights GHRH analogues improving cardiovascular outcomes and neuroprotection in animal models, suggesting promising therapies.
GHRH and insulin hypersecretion from a pancreatic neuroendocrine tumor in multiple endocrine neoplasia type 1
Case report reveals GHRH and insulin cosecretion in a rare pancreatic tumor, suggesting complex endocrine interactions.
Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy
Observational study evaluates weight and glycaemic control improvements in partial lipodystrophy, suggesting tirzepatide's efficacy.
Characterization of intestinal immune responses in generalized human and murine lipodystrophy
Findings characterize immune responses in lipodystrophy, suggesting a unique mechanism for inflammation.
Lipodystrophy Look-Alikes: Navigating Diagnostic Overlap with Endocrine Diseases
This review highlights the diagnostic challenges of lipodystrophy overlap with endocrine diseases, suggesting improved recognition.
Researchers studying Tesamorelin
Researcher network data is loading or unavailable for this topic.
Follow Tesamorelin literature with AI-enriched clinical evidence on Synapse.
Search Tesamorelin on SynapsePowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers